GSK sees profit soar on consumer health spinoff

Published On 2023-02-01 04:00 GMT   |   Update On 2023-02-01 11:55 GMT
Advertisement

London: British pharmaceutical giant GlaxoSmithKline on Wednesday announced soaring annual profits thanks to the demerger of its consumer healthcare unit Haleon.

Net profit surged to £14.9 billion ($18.3 billion) last year from £4.4 billion in 2021, GSK said in a statement.
GSK posted a gain of £10.1 billion thanks to the demerger of Haleon, which became London's biggest listing for more than a decade when it was spun off last year.
Advertisement
The company profited last year also from strong sales of its drugs, notably its shingles vaccine Shingrix.
Total annual group revenue jumped 19 percent to £29.3 billion.
"2022 was a landmark year for GSK delivering the step change in performance we committed to, driven by strong growth in speciality medicines and vaccines, including record sales for Shingrix," GSK chief executive Emma Walmsley said in the earnings statement.
"We enter 2023 with good momentum."
Following the update, GSK's share price rose 0.4 percent to £14.28 on London's top tier FTSE 100 index, which was up 0.1 percent overall in early trading.
"Today's full year results would appear to suggest that the business is heading in the right direction with fourth-quarter profits beating expectations," noted Michael Hewson, chief market analyst at CMC Markets UK.

Read also: WuXi Biologics, GSK enter into license agreement on multiple novel Bi- & Multi-specific T cell engagers

Tags:    
Article Source : AFP

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News